Statin Therapy in Elderly Females with Borderline ASCVD Risk

Risk Classification and Treatment Threshold

The American College of Cardiology and American Heart Association establish a 7.5% 10-year ASCVD risk as the primary threshold for initiating statin therapy in adults aged 40-75 years with LDL-C ≥70 mg/dL 2, 3, 1
At 5.8% risk, this patient falls into the borderline risk category (5% to <7.5%), where moderate-intensity statin therapy is only a Class IIa recommendation (reasonable to consider, not strongly recommended) 1
The number needed to treat at this risk level is 57-67 to prevent one ASCVD event, versus a number needed to harm of 100 for new-onset diabetes 1

Female sex is an independent risk factor for statin-related adverse events, particularly muscle symptoms, myalgias, and weakness 4, 5
Life expectancy must be carefully assessed, as statins require 1-3 year lag time before demonstrable benefit for CHD and stroke, respectively 4, 5
Patients with severe frailty, severe dementia, or conditions severely compromising quality of life may not be suitable candidates despite calculated risk 4

CAC scoring provides objective data to guide treatment decisions in borderline-risk patients, with a CAC = 0 strongly supporting withholding statin therapy (10-year event rate only 1.5%) 6, 7, 1
A CAC 1-99 favors statin therapy, especially in those ≥55 years of age 1
A CAC ≥100 or ≥75th percentile makes statin therapy clearly indicated 1

Start with moderate-intensity statin therapy (atorvastatin 10-20 mg, rosuvastatin 5-10 mg, or simvastatin 20-40 mg) targeting 30-40% LDL-C reduction 4, 5, 1
Initiate at the lowest dose and judiciously titrate as tolerated in elderly patients 4, 5
Avoid high-intensity statins in elderly women due to increased adverse event risk 4, 5

Before any statin prescription, conduct a structured discussion addressing potential ASCVD risk reduction benefits, potential adverse effects, drug-drug interactions, patient's goals of therapy and quality of life priorities, time to treatment benefit, and patient preferences and values 4, 5, 1

Emphasize lifestyle interventions as foundational therapy, including a Step II AHA diet with reduced saturated fat and increased fiber, increased physical activity, weight management if overweight, and smoking cessation if applicable 4, 1, 8

Do not automatically prescribe statins based on age alone—elderly patients require careful assessment of life expectancy, frailty, comorbidities, and quality of life 4, 6, 7
Do not ignore the increased risk of adverse events in elderly females, particularly muscle-related symptoms that can be debilitating and contribute to frailty 4, 5
Do not use risk calculation alone without the mandatory clinician-patient discussion 1
Do not prescribe high-intensity statins in elderly women at borderline risk due to disproportionate adverse event risk 4, 5